Most Read Articles
Dr Margaret Shi, 18 May 2020

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Christina Lau, 12 May 2020

Patients with advanced non-small-cell lung cancer (NSCLC) who have a past medical history of pneumonitis are at increased risk of treatment-related pneumonitis (TAP) from immune checkpoint inhibitor (ICI) regimens or chemotherapy alone, an analysis of clinical trial and real-world data has shown.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
Dr Margaret Shi, 14 May 2020
Pembrolizumab monotherapy improves overall survival (OS) and cancer control compared with platinum-based chemotherapy in patients with untreated locally advanced or metastatic programmed death-ligand 1 (PD-L1)–positive non-small-cell lung cancer (NSCLC) regardless of STK11 or KEAP1 mutation status, according to results of the phase III KEYNOTE-042 study. 

Novel PET-CT method superior to conventional imaging in detecting high-risk localized prostate cancer

Pank Jit Sin
31 Mar 2020
A novel imaging technique using prostate-specific membrane antigen positron emission tomography – computed tomography (PSMA PET-CT) is a suitable replacement for conventional imaging, a study reveals. [Lancet doi.org/10.1016/S0140-6736(20)30314-7]


The multicenter, two-arm, randomized study looked at men with biopsy-proven prostate cancer and high-risk features at 10 hospitals in Australia. [Australian New Zealand Clinical Trials Registry ANZCTR12617000005358] Patients were randomized to undergo either conventional CT and bone scanning or gallium-68 PSMA-11 PET-CT. First-line imaging was performed within 21 days of randomization. Patients were crossed over unless three or more distant metastases were identified. The study’s primary outcome looked at the accuracy of first-line imaging for identifying either pelvic nodal or distant-metastatic diseases, which is defined by the receiver-operating curve using a predefined reference standard, and includes histopathology, imaging and biochemistry at 6-month follow-up.

The study found that PSMA PET-CT had a 27 percent (95 percent CI 23–31) greater accuracy compared to conventional imaging (92 percent [88–95] vs 65 percent [60–69]; p<0.0001). Additionally, conventional imaging was less sensitive and specific compared to PSMA PET-CT. PSMA PET-CT also proved to be superior to conventional imaging for patients with pelvic nodal metastases and patients with distant metastases.

The study also noted that radiation exposure was higher in conventional imaging compared with PSMA PET-CT (19.2 mSv vs 8.4 mSv; p<0.001).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 18 May 2020

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Christina Lau, 12 May 2020

Patients with advanced non-small-cell lung cancer (NSCLC) who have a past medical history of pneumonitis are at increased risk of treatment-related pneumonitis (TAP) from immune checkpoint inhibitor (ICI) regimens or chemotherapy alone, an analysis of clinical trial and real-world data has shown.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
Dr Margaret Shi, 14 May 2020
Pembrolizumab monotherapy improves overall survival (OS) and cancer control compared with platinum-based chemotherapy in patients with untreated locally advanced or metastatic programmed death-ligand 1 (PD-L1)–positive non-small-cell lung cancer (NSCLC) regardless of STK11 or KEAP1 mutation status, according to results of the phase III KEYNOTE-042 study.